Get to know our clinical trials

Clinical trial of TLR7/8 TransCon, in monotherapy or in combination with pembrolizumab, in participants with locally advanced or metastatic malignant solid tumors.

THE OBJECTIVE OF THIS RESEARCH IS TO KNOW THE EFFECTS, GOOD AND/OR BAD, THAT AN EXPERIMENTAL DRUG CALLED TLR7/8 AGONIST TRANSCON HAS WHEN ADMINISTERED IN MONOTHERAPY OR IN COMBINATION WITH ANOTHER ANTICANCER DRUG CALLED PEMBROLIZUMAB.

Status
In recruitment
headquarters
Multisede

Technical Summary

  • Code EudraCT: -
  • Protocol number: TCTLR-101

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial

I want to make an appointment
Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.

I WANT TO REQUEST A SECOND OPINION